Obestatin: appetite-related gut peptide from the ghrelin gene
A natural peptide made in the stomach alongside ghrelin; originally thought to suppress appetite, but those effects were not confirmed in humans; experimental, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Endogenous peptide — produced naturally and routinely synthesized for research
Fork this card to add platform evidence →
Endogenous peptide — receptor binding and activity established in published literature
Fork this card to add platform evidence →
What this is
Obestatin is a 23-amino acid peptide encoded by the ghrelin gene (GHRL) — the same gene that produces ghrelin — arising from proteolytic cleavage of the C-terminal region of preproghrelin. Its name derives from the Latin obedere (to eat up) combined with the inhibitory suffix -statin, reflecting the original proposed function as an appetite-suppressing counterpart to ghrelin. Obestatin is produced in gastric oxyntic cells, small intestine, pancreas, and brain. In its native form the peptide carries a C-terminal amide — a post-translational modification not reflected in the stored one-letter sequence — with some studies suggesting the amidated form is more bioactive in certain assays.
Obestatin was discovered in 2005 and immediately attracted intense research interest as a potential endogenous antagonist of ghrelin's appetite-stimulating effects. However, the core claims of the original report — particularly that obestatin acts through the G-protein-coupled receptor GPR39 to suppress food intake — were not replicated by multiple independent laboratories and were subsequently refuted. Obestatin's true receptor and physiological role remain subjects of ongoing investigation; the compound has no approved clinical indication and is not in active clinical development as a therapeutic.
History
Obestatin was identified by Zhang and colleagues at Stanford University (Zhang et al., Science 2005). The discovery paper used computational analysis of the preproghrelin precursor sequence to predict C-terminal processed peptides, identified obestatin as a candidate, and demonstrated in rats that exogenous obestatin reduced food intake, suppressed jejunal smooth muscle contractions, reduced body-weight gain, and that these effects were abolished in the presence of a GPR39 antagonist, suggesting GPR39 as the obestatin receptor (Zhang et al. 2005).
The Science paper generated widespread scientific interest, given that a second peptide from the ghrelin gene with opposing effects on appetite would constitute a remarkable biological counter-regulatory mechanism. However, over the following two years, multiple independent groups attempted to replicate the core findings:
- Chartrel et al. (2007) and Gourcerol et al. (2007): Could not reproduce the anorexigenic effects of obestatin in rodents.
- Nogueiras et al. (2007): Found no effect of obestatin on food intake, energy expenditure, or body weight in multiple mouse models.
- Holst et al. and subsequent receptor pharmacology studies: Demonstrated that GPR39's endogenous ligand is zinc (Zn²⁺), not obestatin, and that obestatin does not activate GPR39 in heterologous expression systems under controlled conditions.
By 2008, the refutation was explicit in the peer-reviewed literature. Yang and colleagues (Yang et al. 2008), while focused on identifying GOAT (ghrelin O-acyltransferase) as the enzyme responsible for ghrelin octanoylation, stated directly that the claim that obestatin binds a G protein-coupled receptor and acts as a ghrelin antagonist "has been refuted (Chartrel et al., 2007; Gourcerol et al., 2007; Nogueiras et al., 2007)."
Research on obestatin has continued with more modest claims: some laboratories have reported effects on GI motility, pancreatic β-cell function, cell proliferation pathways, and circulating obestatin levels as biomarkers in metabolic disease. Whether these represent genuine obestatin biology or off-target/species-specific effects remains unresolved.
What it does
Shared genetic locus with ghrelin: Both obestatin and ghrelin arise from the GHRL gene on chromosome 3p25. The preproghrelin precursor (117 aa) is cleaved to yield ghrelin (the N-terminal 28-aa peptide, octanoylated at Ser3 for full activity) and obestatin (the C-terminal 23-aa peptide, amidated at its C-terminus). While ghrelin and obestatin share a gene, they do not share a receptor, and the widely circulated notion that they are a paired agonist/antagonist system has not been confirmed.
GI motility effects (species-dependent): The original Zhang and colleagues (2005) report showed that obestatin reduced jejunal contractions in rats. Some subsequent studies in rodent intestinal preparations confirmed inhibitory effects on GI smooth muscle. However, these effects were not consistently reproduced in human tissue or human subjects. A clinical study found that obestatin concentrations did not correlate with weight changes, food intake, or nutritional behaviors in elderly women, and no association with anorexia was found in human populations (Polishchuk et al. 2025).
Pancreatic effects: Some in vitro studies have reported that obestatin stimulates insulin secretion and promotes pancreatic β-cell survival and proliferation. These findings remain incompletely replicated and do not constitute an established pharmacological mechanism.
Circulating biomarker correlations: Plasma obestatin levels have been measured in studies of obesity, metabolic syndrome, type 2 diabetes, and bariatric surgery. Correlations between obestatin levels and metabolic parameters have been reported but are inconsistent across studies, likely reflecting methodological differences in obestatin immunoassay specificity. The plasma half-life of obestatin is short (minutes), and the bioactive form requires C-terminal amidation.
GHRL gene biology: The fact that ghrelin and obestatin are co-encoded creates biological interest in the ghrelin/obestatin ratio as a potential physiological regulatory parameter. Some studies propose that the ratio of active ghrelin to obestatin in circulation reflects metabolic state more reliably than either peptide alone, though this framework has not been prospectively validated.
Evidence
- Human: No therapeutic intervention targeting obestatin has been evaluated in human clinical trials as of 2026. Obestatin plasma levels have been measured as a biomarker in metabolic conditions — obesity, type 2 diabetes, polycystic ovary syndrome — but observational associations from small cohorts are complicated by immunoassay variability and the peptide's very short plasma half-life. Human studies have not demonstrated any connection between obestatin and anorexia or with weight loss (Polishchuk et al. 2025).
- Animal: Zhang and colleagues (2005) showed dose-dependent reduction in food intake and body weight in rats treated with synthetic obestatin over 8 days. Multiple independent groups subsequently failed to reproduce these anorexigenic effects in rodents (Chartrel et al. 2007; Gourcerol et al. 2007; Nogueiras et al. 2007, as documented in Yang et al. 2008).
- In vitro: Some in vitro studies have reported effects on pancreatic β-cell survival and proliferation, and on GI smooth muscle contraction, though results vary across laboratories and conditions.
Myths and misconceptions
- "Obestatin's receptor is GPR39." This was the central claim of the 2005 Science paper (Zhang et al. 2005), but it was refuted. GPR39 is now established to be a zinc-sensing receptor; its endogenous ligand is Zn²⁺, not obestatin. Multiple independent groups failed to reproduce GPR39 activation by obestatin in standardized expression systems. The obestatin receptor, if any dedicated receptor exists, remains unidentified as of 2026.
- "Obestatin suppresses appetite and reduces body weight in humans." The original evidence for this came from rat pharmacology experiments and was not confirmed in subsequent rodent studies or in human subjects. A 2025 comprehensive review of ghrelin-gene biology summarizes that human studies "could not demonstrate any connection between obestatin and anorexia or with weight loss or other dietary issues," indicating potential species-dependent differences in obestatin recognition (Polishchuk et al. 2025).
- "Obestatin 'counters' ghrelin because they're encoded in the same gene." The ghrelin/obestatin co-encoding creates an attractive narrative of a built-in regulatory counter-pair, but this is not supported by evidence. Ghrelin and obestatin have distinct half-lives, different post-translational modifications (ghrelin requires octanoylation at Ser3; obestatin requires C-terminal amidation), and are released in different proportions depending on nutritional state. More importantly, their receptor interactions do not constitute a simple agonist/antagonist pair at the molecular level. The concept of a "balance" between ghrelin and obestatin remains an interpretive framework without mechanistic confirmation.
Common questions
Q: If obestatin's receptor is unknown, how should its biological effects be interpreted? A: In the absence of a confirmed receptor, effects attributed to obestatin must be evaluated with caution. Some laboratories have reported effects in specific tissue preparations (rat intestinal smooth muscle, cultured pancreatic cells) that may reflect direct membrane interactions, non-specific receptor cross-reactivity, or genuine orphan-receptor pharmacology at a yet-unidentified target. Effects that are species-dependent and not reproducible across laboratories are generally considered unreliable evidence of a specific mechanism until the receptor is identified and its pharmacology characterized.
Q: What clinical evidence exists for obestatin's role in human metabolism? A: Obestatin plasma levels have been measured as a biomarker in metabolic conditions — obesity, type 2 diabetes, polycystic ovary syndrome — with some studies reporting correlations with metabolic parameters. However, these are observational associations from small cohorts, complicated by immunoassay variability (antibodies raised against rat obestatin may cross-react differently with human forms) and the peptide's very short plasma half-life. No therapeutic intervention targeting obestatin has been evaluated in human clinical trials as of 2026.
Q: Is obestatin likely to be revisited as a therapeutic target? A: Interest in obestatin as a primary therapeutic target has diminished significantly since the receptor refutation. However, obestatin remains studied as: (1) a potential biomarker of GHRL gene processing, measuring preproghrelin/ghrelin/obestatin processing ratios in metabolic disease; (2) a model system for understanding C-terminal amidated peptide biology from shared-gene precursors, analogous to the POMC gene producing ACTH and β-endorphin; and (3) a cautionary case study in peptide discovery — specifically, the risk of over-interpreting initial in vivo rodent data before receptor pharmacology is established. The obestatin story is now frequently cited in methodological discussions of neuropeptide discovery criteria (Polishchuk et al. 2025).
Related peptides
- Glucagon — Glucagon: a related gut/pancreas peptide from the GCG precursor gene, illustrating how proteolytic processing of a single precursor yields multiple distinct bioactive fragments (glucagon, GLP-1, GLP-2, oxyntomodulin), analogous to the GHRL gene producing ghrelin and obestatin
- Corticotropin — ACTH / Corticotropin: another example of a single precursor gene (POMC) processed to yield multiple bioactive peptides with distinct receptors and functions, contrasting with GHRL where the second fragment's receptor remains unconfirmed
- Urocortin — Urocortin: a CRF-family neuropeptide whose early receptor pharmacology was refined by multiple laboratories over time; illustrates how initial receptor assignment can be revised as more tools become available
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does obestatin actually work through a completely different cell-surface protein than the one first proposed?
If true, scientists could identify a new drug target in the gut or pancreas that controls digestion or blood sugar. This could eventually lead to treatments for obesity, diabetes, or gut disorders that work through a completely fresh biological pathway.
Can obestatin protect the cells that make insulin from dying under the inflammatory conditions seen in diabetes?
If obestatin guards beta cells against destruction, it could lead to a new way to slow or prevent both type 1 and type 2 diabetes. People with diabetes could potentially keep more of their own insulin-producing cells working for longer.
Is obestatin's effect entirely dependent on a chemical modification at its last amino acid that makes it behave like a functional hormone?
If the active tip is just four amino acids long, chemists could build very small, cheap, and stable drug-like molecules that mimic it. That would be far easier to develop into a medicine than the full 23-amino-acid peptide.
Does obestatin dampen ghrelin's hunger-promoting effects by altering signals inside the cell rather than competing for the same docking site?
If true, obestatin points toward a smarter way to target the ghrelin system for weight loss, one that could reduce appetite without shutting down ghrelin's protective effects on the heart. This could lead to safer obesity drugs with fewer cardiovascular side effects.
Does a central stretch of obestatin form a coiled structure only when it contacts a cell surface or partner protein?
Understanding exactly how obestatin folds could help scientists design a more potent, stable version of the peptide. Drugs that work this way can be made to be very selective, reducing unwanted side effects.
▸3-letter notation
▸citationbibtex
@peptide{pep04463,
sequence = {FNAPFDVGIKLSGVQYQQHSQAL},
target = {},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}